Clinical Trial

A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza

Study acronym: ANCHOR
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well CD388 works in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, when given as a single dose via 3 subcutaneous (SQ) injections to adult and adolescent participants who are at higher risk of developing influenza complications, and to evaluate the safety and tolerability of CD388, as compared to placebo.
Protocol Amendment History 9 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-23
notable Enrollment increased: 7500 -> 10000 participants 2026-06-23
notable Primary completion pushed: 2027-01 -> 2027-06 2026-06-23
minor Completion pushed: 2027-01 -> 2027-06 2026-06-23
notable Trial sites expanded: 176 -> 181 locations 2026-06-02
notable Trial sites expanded: 157 -> 176 locations 2026-05-27
critical Trial status changed: Active, Not Recruiting → Recruiting 2026-05-20
notable Trial sites expanded: 150 -> 157 locations 2026-05-20
notable Sponsor changed: Cidara Therapeutics Inc. -> Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 2026-04-19
Trial Details
NCT Number NCT07159763
Lead Sponsor Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Conditions Influenza
Enrollment 10,000 participants
Start Date 2025-09-25
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-22